Neben BioNTech ist Moderna der andere extrem erfolgreiche Impfstoffhersteller in der Corona-Zeit, dessen Erfolg (bislang) nur auf diesem einen Produkt beruht. Vor wenigen Augenblicken hat Moderna seine Quartalszahlen veröffentlicht. Hier die wichtigsten Daten.
Der Umsatz steigt im Jahresvergleich von 157 Millionen Dollar auf 4,97 Milliarden Dollar (für heute im Schnitt von 10 Analysten erwartet 6,2)
Der Gewinn liegt bei 7,70 Dollar pro Aktie nach -0,59 Dollar im Vorjahr (für heute erwartet 9,05).
Der Impfstoffumsatz im gesamten Geschäftsjahr 2021 soll bei 15-18 Milliarden Dollar liegen (bisher erwartet 19,87).
Die Moderna-Aktie reagiert aktuell in der Vorbörse in New York mit -11,8 Prozent.
Hier die Headline-Aussage von Moderna im Wortlaut:
“We are humbled to have helped hundreds of millions of people around the world with our COVID-19 vaccine and yet we know our work is not done. We will not rest until our vaccine is available to anyone who needs it, and we are working hard to ensure our vaccine is available in low-income countries with approximately 10% of our 2021 volume and significantly more of our 2022 volume going to low-income countries. It is promising to see the real-world evidence showing that the Moderna COVID-19 vaccine shows sustainably high, durable efficacy,” said Stéphane Bancel, Chief Executive Officer of Moderna. “Looking ahead, we are focused on advancing the many other programs in our pipeline. We recently dosed the first participants in the Phase 3 study of our CMV vaccine. CMV is a latent virus that remains in the body for life after infection and can lead to lifelong medical conditions. We are also focused on addressing respiratory viruses in addition to COVID-19, including seasonal flu and RSV. We look forward to sharing data from the Phase 1 study of our flu vaccine candidate soon and we are preparing to start our Phase 2 study. We are also preparing to start the Phase 2/3 study of our RSV vaccine candidate. RSV causes hospitalizations and deaths in our most vulnerable populations of young children and older adults. In addition, we continue to progress our therapeutics pipeline and we look forward to clinical proof of concept data. I would like to thank the Moderna team for their scientific passion and commitment to our mission. I am more energized than ever by the impact our mRNA platform will have on human health.”
Kommentare lesen und schreiben, hier klicken
